UMR 152 Pharma Dev, Université de Toulouse, IRD, UPS, France.
UMR 5623 Laboratoire des IMRCP, Université de Toulouse, CNRS, UPS, France.
Cancer Immunol Res. 2019 Feb;7(2):321-334. doi: 10.1158/2326-6066.CIR-18-0213. Epub 2019 Jan 4.
Macrophage-mediated cytotoxicity is controlled by surface receptor expression and activation. Despite the numerous studies documenting the role of macrophage C-type lectin receptors (CLR) in pathogen elimination, little is known about their contribution to antitumor responses. Here, we report that IL13 inhibits T-cell lymphoma and ovarian adenocarcinoma development in tumor-bearing mice through the conversion of tumor-supporting macrophages to cytotoxic effectors, characterized by a CLR signature composed of dectin-1 and mannose receptor (MR). We show that dectin-1 and MR are critical for the recognition of tumor cells through sialic acid-specific glycan structure on their surface and for the subsequent activation of macrophage tumoricidal response. Finally, we validated that IL13 antitumor effect mediated by dectin-1 and MR overexpression on macrophages can extend to various types of human tumors. Therefore, these results identify these CLRs as potential targets to promote macrophage antitumor response and represent an attractive approach to elicit tumor-associated macrophage tumoricidal properties.
巨噬细胞介导的细胞毒性受表面受体表达和激活的控制。尽管有大量研究记录了巨噬细胞 C 型凝集素受体 (CLR) 在病原体清除中的作用,但对于它们在抗肿瘤反应中的贡献知之甚少。在这里,我们报告说,IL13 通过将肿瘤支持性巨噬细胞转化为具有 CLR 特征的细胞毒性效应物来抑制荷瘤小鼠中的 T 细胞淋巴瘤和卵巢腺癌的发展,该特征由包含 dectin-1 和甘露糖受体 (MR) 的组成。我们表明,dectin-1 和 MR 对于通过其表面上的唾液酸特异性聚糖结构识别肿瘤细胞以及随后激活巨噬细胞杀伤反应至关重要。最后,我们验证了通过巨噬细胞上的 dectin-1 和 MR 过表达介导的 IL13 抗肿瘤作用可以扩展到各种类型的人类肿瘤。因此,这些结果将这些 CLR 鉴定为促进巨噬细胞抗肿瘤反应的潜在靶标,并代表了一种有吸引力的方法来引发肿瘤相关巨噬细胞的杀伤特性。